1. The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low- grade dysplasia: results from a randomized controlled trial (SURF trial) 
K. Nadine Phoa, MD, PhD, Wilda D. Rosmolen, BSc, Bas L.A.M. Weusten, MD, PhD, Raf Bisschops, MD, PhD, Erik J. Schoon, Shefali Das, BSc, Krish Ragunath, MD, PhD, G. Fullarton, MD, PhD, Massimiliano DiPietro, MD, PhD, Narayanasamy Ravi, MD, Jan G.P. Tijssen, PhD, Marcel G.W. Dijkgraaf, PhD, Jacques J.G.H.M. Bergman, MD, PhD 
Gastrointestinal Endoscopy 
Volume 86, Issue 1, Pages e2 (July 2017)
DOI: /j.gie
Copyright © 2017 American Society for Gastrointestinal Endoscopy Terms and Conditions

2. Figure 1
Cost-effectiveness plane showing the mean differences in costs between ablation and control after 1000 bootstrap replications. The y axis shows the differences in mean subcosts before neoplastic progression (A) and the total costs including downstream costs for treatment of neoplastic progression (B). The x axis shows the differences in prevented events of neoplastic progression. Ablation was more effective at a higher cost.
Gastrointestinal Endoscopy  , e2DOI: ( /j.gie )
Copyright © 2017 American Society for Gastrointestinal Endoscopy Terms and Conditions

3. Figure 2
Probability of ablation being cost-effective, defined as the proportion of the incremental cost-effect pairs that are cost-effective for a given willingness-to-pay threshold.
Gastrointestinal Endoscopy  , e2DOI: ( /j.gie )
Copyright © 2017 American Society for Gastrointestinal Endoscopy Terms and Conditions